We are live on ! Find out more
RCKT icon

Rocket Pharmaceuticals
RCKT

177 hedge funds and large institutions have $3.4B invested in Rocket Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 60 funds opening new positions, 52 increasing their positions, 49 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

567% more first-time investments, than exits

New positions opened: 60 | Existing positions closed: 9

169% more capital invested

Capital invested by funds: $1.26B → $3.4B (+$2.14B)

133% more funds holding in top 10

Funds holding in top 10: 3 → 7 (+4)

40% more funds holding

Funds holding: 126 → 177 (+51)

3.72% more ownership

Funds ownership: 100.12% → 103.84% (+3.7%)

6% more repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 49

36% less call options, than puts

Call options by funds: $7.09M | Put options by funds: $11.1M

Holders
177
Holders Change
+51
Holders Change %
+40.48%
% of All Funds
3.13%
Holding in Top 10
7
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+133.33%
% of All Funds
0.12%
New
60
Increased
52
Reduced
49
Closed
9
Calls
$7.09M
Puts
$11.1M
Net Calls
-$3.97M
Net Calls Change
-$4.75M

Top Buyers

1
RCM
RA Capital Management
Massachusetts
+$77.9M
2
PA
Perceptive Advisors
New York
+$44M
3
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$43.7M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$40.8M
5
Wellington Management Group
Wellington Management Group
Massachusetts
+$36.5M

Top Sellers

1
EAM
Eventide Asset Management
Massachusetts
-$35.4M
2
VC
Vivo Capital
California
-$20.1M
3
State Street
State Street
Massachusetts
-$17.4M
4
FM
Frazier Management
Washington
-$13.1M
5
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
-$11M
Name Holding Trade Value Shares
Change 		Change in
Stake
BAM
176
Bellevue Asset Management
Washington
$1K +$875 +24 New
EAM
177
Eventide Asset Management
Massachusetts
– -$35.4M -1,550,000 Closed
O
178
OrbiMed
New York
– -$5.79M -253,108 Closed
OCM
179
Osterweis Capital Management
California
– -$3.07M -134,310 Closed
MPAM
180
Monarch Partners Asset Management
Massachusetts
– -$596K -26,090 Closed
DA
181
Duality Advisers
Florida
– -$234K -10,240 Closed
PFS
182
Prospera Financial Services
Texas
– -$84K -3,678 Closed
MAM
183
Meeder Asset Management
Ohio
– -$12K -556 Closed
TFS
184
TrustCore Financial Services
Tennessee
– -$1K -56 Closed
GT
185
Glenmede Trust
Pennsylvania
– -$1K -48 Closed
IA
186
IFP Advisors
Florida
– +$583 +16 New
4 5 6 7
8

RCKT Hedge Fund Activity: Q4 2020 in Review

177 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals (RCKT) for Q4 2020, worth a combined $3.4B — up 169% from $1.26B a quarter earlier.

Buyers outnumbered sellers: 60 funds opened new RCKT positions and 9 closed out — a net gain of 51 holders — while 52 added to existing stakes and 49 trimmed.

The largest buyer was RA Capital Management, opening a new position worth an estimated $77.9M. The largest seller was Eventide Asset Management, exiting entirely with an estimated $35.4M sold.

  • 177 institutional investors held Rocket Pharmaceuticals (RCKT) as of Q4 2020, up from 126 in Q3 2020.
  • Funds reported $3.4B of Rocket Pharmaceuticals stock for Q4 2020, up 169% quarter-over-quarter.
  • 60 funds opened new Rocket Pharmaceuticals positions in Q4 2020 and 9 closed out, a net change of +51 holders.
  • The largest Rocket Pharmaceuticals buyer in Q4 2020 was RA Capital Management, an estimated $77.9M added.
  • The largest Rocket Pharmaceuticals seller in Q4 2020 was Eventide Asset Management, an estimated $35.4M sold.

Based on aggregated 13F filings for Q4 2020.